NCT01870986 - Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01) | Biotech Hunter

Enrollment

210

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions

Healthy

Interventions

BIOLOGICAL

PF-06410293

40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.

BIOLOGICAL

Humira (adalimumab-EU)

40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.

BIOLOGICAL

Humira (adalimumab-US)

40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.

Trial Locations (2)

Pfizer Investigational Site, New Haven

Pfizer Investigational Site, Brussels